# Filing Detail

Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001193125-21-300184
Filing Date
2021-10-15
Accepted
2021-10-15 17:25:36
Documents
11

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 424B4 | d111280d424b4.htm | 424B4 | 1497201
2 | GRAPHIC | g111280g13a26.jpg | GRAPHIC | 128691
3 | GRAPHIC | g111280g19z56.jpg | GRAPHIC | 119660
4 | GRAPHIC | g111280g22b02.jpg | GRAPHIC | 93295
5 | GRAPHIC | g111280g22c03.jpg | GRAPHIC | 59931
6 | GRAPHIC | g111280g22d04.jpg | GRAPHIC | 47334
7 | GRAPHIC | g111280g22f06.jpg | GRAPHIC | 70013
8 | GRAPHIC | g111280g36z36.jpg | GRAPHIC | 125676
9 | GRAPHIC | g111280g45c49.jpg | GRAPHIC | 54760
10 | GRAPHIC | g111280g72l45.jpg | GRAPHIC | 124475
11 | GRAPHIC | g111280g89a09.jpg | GRAPHIC | 46421
| Complete submission text file | 0001193125-21-300184.txt |  | 2657640

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: 424B4 | Act: 33 | File No.: 333-259503 | Film No.: 211326818
SIC: 2836 Biological Products, (No Diagnostic Substances)